Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

18
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
18
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

13
Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
13
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

20
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
20
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

13
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
13
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

13
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
13
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

22
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
22

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

Predictive Value of the Pulmonary Artery Pulsatility Index in Pulmonary Arterial Hypertension: REVEAL Analysis.

Cardiology research·2026
Same journal

Comparison of Single-Freezing Temperature-Guided and Conventional Time-to-Isolation-Guided Protocols of Cryoballoon in Atrial Fibrillation Ablation.

Cardiology research·2026
Same journal

Sardjito Cardiovascular Intensive Care Score as an Alternative to Mayo Cardiac Admission Risk Score for Predicting Mortality in Cardiovascular Intensive Care Patients.

Cardiology research·2026
Same journal

Strong Adherence to Cardiac Rehabilitation Program Improves Exercise Tolerance in Outpatients With Cardiovascular Disease.

Cardiology research·2026
Same journal

Association of Circulating Brain-Derived Neurotrophic Factor With Coronary Risk Factors and Coronary Artery Disease in Patients Who Have Undergone Coronary Computed Tomography Angiography.

Cardiology research·2026
Same journal

Role of Intracoronary Imaging in Percutaneous Coronary Intervention for In-Stent Restenosis: A Prospective Observational Study.

Cardiology research·2026

Related Experiment Video

Updated: Aug 1, 2025

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

10.1K

Immobilizing Interstitial Cardiac Fibrosis.

Yuriy L Shevchenko1, Alexey V Plotnitsky1, Daniil S Ulbashev1

  • 1St. George Clinic of Thoracic and Cardiovascular Surgery, Pirogov National Medical & Surgical Center, 105203 Moscow, Russia.

Cardiology Research
|April 24, 2023
PubMed
Summary

Immobilizing interstitial cardiac fibrosis (IICF) stiffens the heart by altering connective tissue, leading to heart failure. This study identifies key molecular markers and associated conditions in IICF patients.

Keywords:
Cardiac fibrosisConnective tissueHeart failureInterstitial

More Related Videos

Refined CLARITY-Based Tissue Clearing for Three-Dimensional Fibroblast Organization in Healthy and Injured Mouse Hearts
07:10

Refined CLARITY-Based Tissue Clearing for Three-Dimensional Fibroblast Organization in Healthy and Injured Mouse Hearts

Published on: May 16, 2021

4.7K
A Hydrogel Construct and Fibrin-based Glue Approach to Deliver Therapeutics in a Murine Myocardial Infarction Model.
06:15

A Hydrogel Construct and Fibrin-based Glue Approach to Deliver Therapeutics in a Murine Myocardial Infarction Model.

Published on: June 14, 2015

8.8K

Related Experiment Videos

Last Updated: Aug 1, 2025

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

10.1K
Refined CLARITY-Based Tissue Clearing for Three-Dimensional Fibroblast Organization in Healthy and Injured Mouse Hearts
07:10

Refined CLARITY-Based Tissue Clearing for Three-Dimensional Fibroblast Organization in Healthy and Injured Mouse Hearts

Published on: May 16, 2021

4.7K
A Hydrogel Construct and Fibrin-based Glue Approach to Deliver Therapeutics in a Murine Myocardial Infarction Model.
06:15

A Hydrogel Construct and Fibrin-based Glue Approach to Deliver Therapeutics in a Murine Myocardial Infarction Model.

Published on: June 14, 2015

8.8K

Area of Science:

  • Cardiology
  • Pathology
  • Biochemistry

Background:

  • Alterations in the endomysium and perimysium can cause cardiomyocyte immobilization, leading to heart stiffening.
  • This process, termed immobilizing interstitial cardiac fibrosis (IICF), hinders normal diastolic and systolic function.
  • Understanding IICF's molecular and structural basis is crucial for addressing heart failure pathogenesis.

Purpose of the Study:

  • To investigate the clinical characteristics and molecular differences in patients with immobilizing interstitial cardiac fibrosis (IICF).
  • To identify associated conditions and biomarkers indicative of IICF.
  • To establish IICF as a distinct pathological entity contributing to heart failure.

Main Methods:

  • Comparative study of 69 patients: 32 with IICF (Group I) and 37 in a control group (Group II).
  • Evaluation included clinical picture, medical history, physical examination, laboratory tests, instrumental examinations, and autopsy data.
  • Analysis focused on differences in disease history, fibrosis volume, and expression of specific proteins (collagens, MMPs, connexin-43, fibronectin, TGF-β).

Main Results:

  • Patients with IICF showed significantly higher prevalence of arrhythmias, connective tissue diseases, viral infections (including SARS-CoV-2), and type 2 diabetes.
  • Statistically significant differences were observed in fibrosis zone volume and expression levels of type I and III collagen, MMP-2, MMP-9, fibronectin, and TGF-β.
  • Conversely, connexin-43 expression was lower in patients with IICF compared to the control group.

Conclusions:

  • Immobilizing interstitial cardiac fibrosis (IICF) is identified as a distinct pathological condition.
  • IICF is a primary contributor to the development of chronic heart failure.
  • Myocardial connective tissue changes in IICF impair normal heart function.